Search | Clinical Trials Finder

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 9 more

Conditions: Acute Ischemic Stroke, Thrombotic Disease
Interventions: DS-1040b, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more

Conditions: Colitis, Ulcerative
Interventions: placebo, MultiStem low dose, MultiStem high dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 37
States / cities: San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more

Conditions: Healthy
Interventions: PF-06480605, Placebo; Drug
Lead sponsor: Telavant, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Peripheral Arterial Disease
Interventions: Angiotensin 1-7, Saline; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Alzheimer's Disease (AD)
Interventions: ABBV-916, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 32
States / cities: Tucson, Arizona • Irvine, California • San Diego, California + 23 more

Conditions: Healthy Volunteer
Interventions: ABBV-8736, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Stroke, Ischemia, Infarction
Interventions: CNTO 0007 or placebo (Stage A), CNTO 0007 or placebo (Stage B); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Portland, Oregon • Houston, Texas

Conditions: Severe Sepsis, Acute Lung Injury
Interventions: High Dose Citrulline, Placebo, Low Dose Citrulline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cerebrovascular Accident
Interventions: GSK249320A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-1-infection
Interventions: 3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 45 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Seattle, Washington

Conditions: Heart Transplantation, Liver Transplantation, Bone Resorption
Interventions: Zoledronic acid, Alendronate, Placebo Zoledronic Acid, Placebo Alendronate; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 20 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Ischemic Stroke
Interventions: DP-b99, Placebo; Drug
Lead sponsor: D-Pharm Ltd.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 13
States / cities: Oceanside, California • Danbury, Connecticut • Savannah, Georgia + 10 more

Conditions: Multiple Myeloma
Interventions: Allogeneic HSCT, Fludarabine, Melphalan, Bortezomib, Ixazomib, Placebo; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Tampa, Florida + 11 more

Conditions: Coronary Disease
Interventions: INS50589 Intravenous Infusion; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Timeline: Started 2006
U.S. locations: 27
States / cities: Birmingham, Alabama • San Diego, California • Springfield, Illinois + 13 more

Conditions: Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity
Interventions: hydrocortisone, saline; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD)
Interventions: alglucosidase alfa; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 8 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 26
States / cities: Anchorage, Alaska • Phoenix, Arizona • Beverly Hills, California + 23 more

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more

Conditions: Obesity
Interventions: Peptide YY3-36; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: NTLA-2001, Placebo; Biological · Drug
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more

Conditions: Bacterial Infections
Interventions: ceftaroline, vancomycin plus aztreonam, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 17
States / cities: Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more

Conditions: Diabetic Kidney Disease (DKD)
Interventions: CSL346, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 25 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Covina, California • Fresno, California • Lomita, California + 15 more

Conditions: Hypercholesterolemia
Interventions: PF-05335810 Dose A, PF-05335810 Dose B, Placebo, PF-04950615 Dose A, PF-05335810 Dose C, PF-04950615, PF-05335810 Dose D, PF-05335810 Dose E; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: New Haven, Connecticut • Miami, Florida • South Miami, Florida + 4 more

Search by objective public record fields.

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

Angiotensin-(1-7) in Peripheral Arterial Disease

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Citrulline in Severe Sepsis

Anti-MAG First Administration to Human

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass

Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger

Late-Onset Treatment Study Extension Protocol

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects